Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Article Type: Editorial
DOI: 10.3233/JAD-2008-14401
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 363-363, 2008
Authors: Iqbal, Khalid | Alonso, Alejandra del C. | Grundke-Iqbal, Inge
Article Type: Research Article
Abstract: Neurofibrillary degeneration of abnormally hyperphosphorylated tau, a hallmark of Alzheimer's disease (AD) and related tauopathies, occurs both as cytosolic aggregated/oligomeric protein (AD P-tau) and as neurofibrillary tangles. The abnormal hyperphosphorylation not only results in the loss of tau function of promoting assembly and stabilizing microtubules but, in the case of the cytosolic AD P-tau, also in a gain of a toxic function whereby the pathological tau sequesters not only normal tau, but also the other two neuronal microtubule associated proteins (MAPs), MAP1A / MAP1B and MAP2, and causes inhibition and disruption of microtubules. The sequestration of normal MAPs leads to …a slow but progressive degeneration of the affected neurons. The affected neurons defend against the toxic tau by continually synthesizing new normal tau as well as by packaging the abnormally hyperphosphorylated tau into polymers, i.e., neurofibrillary tangles of paired helical filaments, twisted ribbons and straight filaments. The filamentous tau is inert; it neither interacts with tubulin and stimulates it assembly, nor binds to normal MAPs and causes disruption of microtubules. These findings suggest the inhibition of tau abnormal hyperphosphorylation and not the aggregation of tau as the preferred therapeutic target for AD and related tauopathies. Show more
Keywords: Abnormal hyperphosphorylation of tau, Alzheimer disease, microtubule associated protein 2, microtubule associated protein tau, microtubules, neurofibrillary degeneration, protein phosphatase-2A, tauopathies
DOI: 10.3233/JAD-2008-14402
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 365-370, 2008
Authors: Takashima, Akihiko
Article Type: Research Article
Abstract: Pathological studies show that neurofibrillary tangles are found in regions where neuronal death occurs. This observation raises the question: Are neurofibrillary tangles toxic or protective? Findings from various mouse models expressing human tau with the FTDP17 mutation suggest that some component involved in the formation of neurofibrillary tangles, rather than the neurofibrillary tangles themselves, might be responsible for the toxicity leading to neuronal death. Here, I review our current understanding of a toxic species of tau and the mechanism by which it contributes to neuronal dysfunction and death. Recent studies suggest that, before forming fibrils but after becoming hyperphosphorylated, tau …is involved in neurodegenerative disease. Show more
Keywords: Entorhinal cortex, granular tau oligomer, hyperphosphorylation, synapse loss, tau
DOI: 10.3233/JAD-2008-14403
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 371-375, 2008
Authors: Castellani, Rudy J. | Nunomura, Akihiko | Lee, Hyoung-gon | Perry, George | Smith, Mark A.
Article Type: Research Article
Abstract: Identification of phosphorylated tau as the major protein component of neurofibrillary tangles (NFTs) led to the concept that phosphorylated tau was inherently toxic and, as such, intimately involved in Alzheimer's disease (AD) pathogenesis. While superficially logical, this construct ignores a number of key findings in AD, including i) that NFTs are encountered in viable neurons until late stage disease; ii) that NFTs persist within the neuronal cytoplasm for decades; iii) that NFTs are encountered, sometimes in significant numbers, in cognitively intact elderly; and iv) that neurons with NFTs contain normal content and structure of microtubules. Experimental data in transgenic animal …models has further demonstrated that NFTs accumulate in neurons in spite of tau suppression and behavior normalization. These data call into question the inherent toxicity of phosphorylated tau, seemingly leaving the only viable hypothesis of the ad hoc “toxic intermediate” phosphorylated tau concept. However, since we also know that phosphorylated tau sequesters redox active heavy metals and protects against oxidative stress, here we suggest that phosphorylated tau serves a protective role against cellular toxicity. Show more
Keywords: Alzheimer's disease, neurofibrillary tangles, phosphorylated tau, protective, toxic
DOI: 10.3233/JAD-2008-14404
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 377-383, 2008
Authors: Pei, Jin-Jing | Björkdahl, Cecilia | Zhang, Haiyan | Zhou, Xinwen | Winblad, Bengt
Article Type: Research Article
Abstract: The 70-kDa S6 kinase (p70S6K) is a Ser/Thr (S/T)-directed kinase that plays a crucial role in cell growth, cell differentiation, and cell cycle control. This article presented evidence that supports both toxic and protective roles of p70S6K activity towards tau in Alzheimer's disease (AD) brains. The p70S6K can phosphorylate tau at S262, S214, and T212 sites. Phosphorylation at these sites might release tau from microtubules, resulting in microtubule disruption. Evidence also suggests that p70S6K regulates the translation of tau mRNA by phosphorylating the 40S ribosomal protein S6. The extracellular amyloid-β deposition in AD brains could be a causative factor that …activates p70S6K. We hypothesized that amyloid-β deposition activates p70S6K whose anti-apoptotic property subsequently keeps neurons from entering into the apoptotic process. This process provides the opportunity for the newly synthesized tau to be phosphorylated by p70S6K and by other tau kinases. This hyperphosphorylated tau then aggregates and is progressively deposited in neurons. Show more
Keywords: Alzheimer's disease, amyloid-β, p70 S6 kinase, tau phosphorylation
DOI: 10.3233/JAD-2008-14405
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 385-392, 2008
Authors: Brunden, Kurt R. | Trojanowski, John Q. | Lee, Virginia M.-Y.
Article Type: Review Article
Abstract: The discovery that mutations within the tau gene lead to frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) provided direct evidence that tau alterations can lead to neurodegenerative disease. While the presence of tau fibrils and tangles is a common feature of all tauopathies, including Alzheimer's disease (AD), data are emerging from biochemical, cell-based and transgenic mouse studies which suggest that a pre-fibrillar form of pathological tau may play a key role in eliciting central nervous system neurodegeneration and behavioral impairments. Herein we review recent findings that implicate diffusible tau pathology in the onset of neurodegeneration, and discuss the …implications of these findings as they relate to tau tangles and possible therapeutic strategies for the treatment of AD and related tauopathies. Show more
Keywords: Fibrils, neurodegeneration, oligomers, tangles, tau, transgenic
DOI: 10.3233/JAD-2008-14406
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 393-399, 2008
Authors: García-Sierra, Francisco | Mondragón-Rodríguez, Siddhartha | Basurto-Islas, Gustavo
Article Type: Research Article
Abstract: Abnormal posttranslational modifications of tau protein lead it to aggregate into paired helical filaments in Alzheimer's disease (AD). The mechanisms involved in the early pathological processing of tau and the induction of a polymeric state seem to progress through a sequential pattern of changes mainly involving abnormal phosphorylation, conformational changes and truncation. While proteolytic cleavage of tau protein during the progression of AD has not been comprehensively analyzed, tau is a substrate for several intracellular proteases. Furthermore, abnormal regulation of proteolytic events, including those associated with apoptosis, may generate truncated tau subproducts which in turn may be toxic to neurons …per se and capable of polymerization at a faster rate. Accumulation of tau fibrils has long been controversial, with much debate concerning the true toxicity of polymerized tau. The development of different transgenic mice overexpressing tau protein, the generation of cell models expressing tau, and the in vitro polymerization paradigms have significantly enhanced our understanding of the biophysics and pathological properties of tau polymers in AD, as well as in other tau pathologies. This review will discuss the pathological role of truncated tau protein in the context of toxicity and neurofibrillary tangle formation and maturation and its significance in clinical dementia. Show more
Keywords: Alzheimer's disease, apoptosis, neurodegeneration, neurofibrillary tangle, tau aggregation
DOI: 10.3233/JAD-2008-14407
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 401-409, 2008
Authors: Rankin, Carolyn A. | Gamblin, T. Chris
Article Type: Research Article
Abstract: Abnormally phosphorylated and aggregated tau protein is the primary component of pathological structures that are closely associated with neurodegeneration in Alzheimer's disease, Pick disease, corticobasal degeneration, progressive supranuclear palsy and many other neurodegenerative tauopathies, leading to the hypothesis that these structures are toxic mediators of disease progression. Results from animal models designed to test this hypothesis have yielded evidence that can suggest either a pathogenic, beneficial, or incidental role for tau aggregation. This review summarizes the differences in construction of recent model systems and assay methods that examine tau pathology and toxicity. We have found that the expression levels of …tau and the modifications of tau used to enhance its aggregation have a large impact on the results. It is clear from the data that tau aggregation is toxic, but it is less clear which form of tau aggregate is the toxic species. Show more
Keywords: Aggregation, Alzheimer's disease, neurofibrillary tangle, tau, toxicity
DOI: 10.3233/JAD-2008-14408
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 411-416, 2008
Authors: Honson, Nicolette S. | Kuret, Jeff
Article Type: Research Article
Abstract: Since its discovery as a structural component of neurofibrillary lesions of Alzheimer's disease more than twenty years ago, tau protein has been implicated in the cascade of events associated with neurodegeneration. Specifically, the “tau hypothesis” posits that misfunction of tau, which occurs in response to unknown stimuli, results in its intracellular assembly into filaments that eventually prove toxic to the cells that produce them. The tau hypothesis is supported by numerous neuropathological and genetic observations of authentic human disease cases. However, experiments designed to study aggregate toxicity in biological models suggest that some aggregate species may be inert or could …potentially serve a neuroprotective function. Distinguishing these possibilities experimentally has been complicated by currently available biological models, which do not fully recapitulate aggregation conditions seen in disease. Additional model systems which better approximate physiological conditions may help elucidate the molecular mechanisms involved in aggregation associated toxicity. Here we examine the accumulated evidence linking aggregation and neurodegeneration, and experimental approaches to the problem of tau aggregation-mediated toxicity. Show more
Keywords: Aggregation, microtubules, neurofibrillary tangle, protein structure, tau
DOI: 10.3233/JAD-2008-14409
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 417-422, 2008
Authors: Götz, Jürgen | Ittner, Lars M. | Fändrich, Marcus | Schonrock, Nicole
Article Type: Research Article
Abstract: In Alzheimer's disease brain, the microtubule-associated protein tau detaches from the microtubules, pathologically interacts with cellular proteins, and eventually forms insoluble aggregates that also bind and trap a myriad of proteins. As these proteins are depleted from the cellular pool, they are unavailable for physiological functions. Thus elevated tau levels are pathogenic, even in the absence of tau aggregation. Whereas it is reasonable to assume that tau aggregation is toxic during late stages of disease, the question arises whether early in disease it may be protective. This question can be addressed in tau transgenic animal models in which tau aggregation …has been correlated with behavioral impairment. We discuss ways of how tau aggregation is monitored in these mice and what the detection limits are of these methods. We conclude that new tools are needed to measure the different stages of tau aggregation. Show more
Keywords: Axonal transport, β-sheet structure, fibril, immuno-precipitation, mass spectrometry, oligomer, phosphorylation, thioflavin, transgenic
DOI: 10.3233/JAD-2008-14410
Citation: Journal of Alzheimer's Disease, vol. 14, no. 4, pp. 423-429, 2008
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]